Akademik Veri Yönetim Sistemi
Journal of Turkish Society For Rheumatology, cilt.13, sa.3, ss.107-115, 2021 (Scopus, TRDizin)
Objective: This study aimed to evaluate the effect of obesity on demographic and clinical features, disease activity indices, and the retention rates of biological disease-modifying antirheumatic drugs (bDMARDs) in psoriatic arthritis (PsA) patients in Hacettepe University Rheumatology Biologic Registry (HUR-BIO). Methods: Patients who were enrolled in the HUR-BIO PsA registry were included. Until February 2020, HUR-BIO PsA registry enrolled 469 patients. Body mass index ≥30 was defined as obesity. Age-and sex-matched 170 obese and 170 non-obese patients were included in the final analysis. Demographic, clinical, laboratory, and therapeutic data were collected from this database. Results: The obese group was significantly older at the age of psoriasis diagnosis and had lower PsA disease duration than the non-obese group. While there was no difference between the two groups in terms of axial involvement, peripheral involvement (ever), smoking (ever), HLA-B27 positivity, uveitis, inflammatory bowel disease, use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and steroid, and distribution of first and last bDMARDs, diabetes mellitus and hypertension were more common in the obese group. Several patient-reported outcomes (PROs) were significantly higher in the obese group than in the non-obese group at the onset of bDMARDs. However, there was no difference in terms of change in PROs from baseline and significant treatment response at the last visit of the obese and non-obese PsA patients. There was no significant difference between the PsA subgroups in the retention rates of the first bDMARDs. However, it was very close to the significance value (log-rank, p=0.055). Conclusion: There was no significant difference in treatment responses between the groups, although baseline disease activity and functions were worse in the obese PsA group than in the the non-obese group. In obese PsA patients, bDMARDs drug retention appears to be worse, although not significant at borderline. Weight loss in obese PsA patients may positively affect the inflammatory burden, retention of bDMARDs and functional parameters.